An international randomised trial of radical surgery followed by adjuvant therapy versus no further treatment in patients with early-stage, intermediate-risk cervical cancer (CERVANTES)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504973-19-01

Enrollment

128

Registered

2023-08-09

Start date

2023-09-06

Completion date

Unknown

Last updated

2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early-stage, intermediate-risk cervical cancer

Brief summary

Disease-free survival [ Time Frame: Analysed 3 years after randomization of the last patient. ]

Detailed description

1. Overall survival. 2.Pelvic disease-free survival. 3. Health-related quality of life based questionnaire. 4. Treatment-related adverse events based on Common Terminology Criteria for Adverse Events v5.0.

Interventions

DRUGCarboplatin Accord 10 mg/ml koncentrát pro přípravu infuzního roztoku

DRUGCarboplatin Kabi 10 mg/ml koncentrát pro infuzní roztok

DRUGCisplatin Ebewe 1 mg/ml koncentrát pro infuzní roztok

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Disease-free survival [ Time Frame: Analysed 3 years after randomization of the last patient. ]	—

Secondary

Measure	Time frame
1. Overall survival. 2.Pelvic disease-free survival. 3. Health-related quality of life based questionnaire. 4. Treatment-related adverse events based on Common Terminology Criteria for Adverse Events v5.0.	—

Countries

Belgium, Czechia, Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026